Neuraxis (NRXS) Change in Receivables (2022 - 2025)
Neuraxis (NRXS) posted Change in Receivables of $87325.0 for Q4 2025, up 590.2% sequentially from -$17814.0 in Q3 2025, and down 50.46% YoY from $176262.0 in Q4 2024.
Neuraxis (NRXS) Change in Receivables (2022 - 2025) Analysis & Trends
Neuraxis has reported Change in Receivables for 4 years, with the latest figure at $87325.0 in Q4 2025.
- Quarterly Change in Receivables fell 50.46% year-over-year to $87325.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$46589.0 (down 126.05% YoY) and the FY2025 annual result came in at -$46589.0, down 126.05% from the prior year.
- Change in Receivables climbed to $87325.0 in Q4 2025 per NRXS's latest filing, from -$17814.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $185299.0 in Q1 2023 and troughed at -$169135.0 in Q4 2022.
- A 4-year average of $224.57 and a median of -$9362.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables soared 537.22% in 2024, then plunged 282.95% in 2025.
- Over 4 years, Change in Receivables stood at -$169135.0 in 2022, then jumped by 76.16% to -$40314.0 in 2023, then jumped by 537.22% to $176262.0 in 2024, then tumbled by 50.46% to $87325.0 in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered $87325.0, -$17814.0, and -$115190.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 87,325.00 |
| Dec 31, 2025 | 87,325.00 |
| Sep 30, 2025 | -17,814.00 |
| Sep 30, 2025 | -17,814.00 |
| Jun 30, 2025 | -115,190.00 |
| Jun 30, 2025 | -115,190.00 |
| Mar 31, 2025 | -910.00 |
| Mar 31, 2025 | -910.00 |
| Dec 31, 2024 | 176,262.00 |
| Dec 31, 2024 | 176,262.00 |
| Sep 30, 2024 | -91,381.00 |
| Sep 30, 2024 | -91,381.00 |
| Jun 30, 2024 | 62,963.00 |
| Jun 30, 2024 | 62,963.00 |
| Mar 31, 2024 | 31,001.00 |
| Mar 31, 2024 | 31,001.00 |
| Dec 31, 2023 | -40,314.00 |
| Dec 31, 2023 | -40,314.00 |
| Sep 30, 2023 | -102,335.00 |
| Sep 30, 2023 | -102,335.00 |